Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics Inc. is the issuer in a Schedule 13D by the James Russell Revocable Trust and James Russell, as trustee, reporting beneficial ownership of 3,479,963 shares, or 6.1%, with shared voting and dispositive power. The percentage is based on 57,184,017 shares outstanding as of August 10, 2026. The Trust reports acquiring the shares with personal funds for approximately $17,776,513, excluding brokerage commissions, including 759,088 shares acquired since its prior Schedule 13G for approximately $3,671,466.
The reporting persons state they no longer hold the shares solely for passive investment purposes and intend to continue engaging with Abeona’s Board and management. Depending on the Board’s response and other factors, they may propose or seek director nominees for the 2027 annual meeting, vote against one or more incumbent directors, communicate with other stockholders, or seek Board representation. They will not vote shares acquired on or after October 15, 2026, at any stockholder meeting.
Abeona Therapeutics (ABEO) Chief Executive Officer Seshadri Vishwas sold 19,608 shares of common stock on September 29, 2026. The weighted average sale price was $5.1556 per share, with individual sale prices ranging from $5.1150 to $5.3000. The sale was to cover tax obligations associated with vesting restricted stock awards; Vishwas directly held 1,286,500 shares afterward. No Rule 10b5-1 plan is reported.
Abeona Therapeutics Inc. Chief Financial Officer Joseph Walter Vazzano sold 9,191 shares of common stock on September 29, 2026, at a weighted average price of $5.1556 per share. The shares were sold in multiple transactions at prices ranging from $5.1150 to $5.3000 to cover tax obligations associated with vesting restricted stock awards. He directly held 482,888 shares after the sale; no Rule 10b5-1 plan is reported.
Abeona Therapeutics Inc. (ABEO) SVP and Chief Legal Officer Brendan M. O'Malley sold 6,727 shares of common stock on September 29, 2026, at a weighted average price of $5.1556 per share. The sale covered tax obligations associated with vesting restricted stock awards; the shares were sold in multiple transactions at prices ranging from $5.1150 to $5.3000 per share. O'Malley directly held 421,226 shares after the sale, and no Rule 10b5-1 plan is reported.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada sold 4,902 common shares on September 29, 2026, at a weighted average price of $5.1556 per share. The sale covered tax obligations associated with vesting restricted stock awards; individual sales ranged from $5.1150 to $5.3000. He directly held 285,721 shares after the sale. No Rule 10b5-1 plan is reported.
Abeona Therapeutics Inc. (ABEO) officer Joseph Walter Vazzano reported a proposed sale of 9,191 common shares, listed at an aggregate market value of $47,385, with an approximate sale date of September 29, 2026. The securities table separately lists 18,186 common shares acquired from the issuer as restricted stock awards on September 29, 2026. The remarks state that the shares listed for sale were sold to cover taxes pursuant to an RSA vesting event.
Abeona Therapeutics Inc. officer Vishwas Seshadri's Form 144 notice lists 19,608 common shares for sale through Stifel Nicolaus & Company Inc., with an approximate sale date of September 29, 2026 and an aggregate market value of $101,091. The remarks state that the shares were sold to cover taxes pursuant to an RSA vesting event.
Abeona Therapeutics Inc. (ABEO) reports a Form 144 notice by officer Madhav Vasanthavada covering a proposed sale of 4,902 common shares, with an aggregate market value of $25,273. The approximate sale date is September 29, 2026; Stifel Nicolaus & Company Inc. is listed as broker, and Nasdaq as the exchange.
Abeona Therapeutics Inc. (ABEO) lists 6,727 common shares for sale for officer Brendan M. O'Malley, with an aggregate market value of $34,682.00 and an approximate sale date of September 29, 2026. The remarks say the shares were sold to cover taxes in connection with a restricted stock award vesting event. Stifel Nicolaus & Company Inc. is listed as broker; Azad Daswani signed as its duly authorized representative and O'Malley's attorney-in-fact. The notice also lists 12,050 shares sold on July 9, 2026, for $83,913.00.
Abeona Therapeutics Inc. (ABEO) furnished an updated investor presentation as a Regulation FD disclosure in connection with its participation on September 15, 2026 at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation is provided as Exhibit 99.1 to this report.
The company states that the materials in Item 7.01, including Exhibit 99.1, are being furnished rather than filed under the Exchange Act and will only be incorporated into other securities law filings if specifically referenced.